UCART20x22 preclinical data presented at AACR demonstrated PoC with robust in vitro and in vivo anti-tumor activity. Received a $20 million convertible note under collaboration agreement with its partner Cytovia Therapeutics. US FDA has allowed an IND to proceed for Iovance Biotherapeutics first genetically modified TIL therapy.
💼 Business Developments:
✅ Partnership/Collaboration
✅ Acquisition Activity
✅ Licensing Agreement
❌ Regulatory Milestone: Not reported
❌ Leadership Updates: Not reported
📞 Contact Information:
Media Contact: s: Pascalyne Wilson, Director, Communications, +33776991433, media@cellectis.com
🌍 Cellectis (CLLS) - Form 6-K Filing
Filing Date: 2022-05-12
Accepted: 2022-05-12 16:40:47
Event Type: Clinical Trial Update
Event Details:
💼 Business Developments:
📞 Contact Information: